Pfizer Chantix Review Shows Pitfalls Of Patient-Reported Outcomes
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
The debate over analysis of clinical trial endpoints in FDA review documents for Pfizer’s Chantix (varenicline) provides a window into how the agency’s view of smoking cessation trial design is changing as new therapeutic classes emerge.